Abstract:Following the publication of the above article, the authors have realized that there was one misplaced image in Fig. 1D (the immunoblot shown for active caspase 3), and also a misplaced image in Fig. 3C (the LP1 0‑48 h data for caspase 9). The corrected versions of Figs. 1 and 3 are presented opposite and on the next page, showing the correct data as specified. Note that these errors did not impact the conclusions of the manuscript, due to the similarity of the correct data to the misplaced data. In addition, the acknowledgements were not accurately described. The Acknowledgements section should have been written as follows: “The present study was supported by Research Fund for Teachers in Jinan University (to J.P.)”. All the authors agree with this corrigendum. We would like to thank the Editor of Oncology Letters for given us the opportunity to publish this corrigendum, and sincerely apologize to the readers for our inadvertent errors that were introduced during the preparation and revision of manuscript. [the original article was published in Oncology Letters 15: 5871‑5878, 2018; DOI: 10.3892/ol.2018.8006]

Correction to: Novel smac mimetic APG-1387 elicits ovarian cancer cell killing through TNF-alpha, Ripoptosome and autophagy mediated cell death pathway (Journal of Experimental and Clinical Cancer Research (2018) 37 (53) DOI: 10.1186/s13046-018-0703-9)

Correction To: Novel Smac Mimetic APG-1387 Elicits Ovarian Cancer Cell Killing Through TNF-alpha, Ripoptosome and Autophagy Mediated Cell Death Pathway

Correction to: Cryptotanshinone activates AMPK-TSC2 axis leading to inhibition of mTORC1 signaling in cancer cells

Corrigendum for “A Novel Kinase Subverts Aluminium Resistance by Boosting Ornithine Decarboxylase‐dependent Putrescine Biosynthesis”

Correction To: Early Presence of Anti-Angiogenesis-related Adverse Events As a Potential Biomarker of Antitumor Efficacy in Metastatic Gastric Cancer Patients Treated with Apatinib: a Cohort Study

Correction To: Therapeutic Efficacy, Pharmacokinetic Profiles, and Toxicological Activities of Humanized Antibody-Drug Conjugate Zt/g4-MMAE Targeting RON Receptor Tyrosine Kinase for Cancer Therapy

Erratum: the Novel BH-3 Mimetic Apogossypolone Induces Beclin-1- and ROS-mediated Autophagy in Human Hepatocellular Carcinoma Cells

Erratum: Recombinant Mutated Human TNF in Combination with Chemotherapy for Stage IIIB/IV Non-Small Cell Lung Cancer: A Randomized, Phase III Study.

Correction to: Therapeutic efficacy of the novel SHP2 degrader SHP2-D26, alone or in combination, against lung cancer is associated with modulation of p70S6K/S6, Bim and Mcl-1

Correction: Lertsuwan et al. CX-4945 Induces Methuosis in Cholangiocarcinoma Cell Lines by a CK2-Independent Mechanism. Cancers 2018, 10, 283

Erratum: Novel permissive murine immunocompetent orthotopic colon carcinoma model for comparison of the antitumoral and safety profiles of three Adv-TKs

Corrigendum to: Investigation of the Apoptosis Inducing and β-catenin Silencing by Tetradentate Schiff Base Zinc(II) Complex on the T-47D Breast Cancer Cells

Correction to: Nanog interaction with the androgen receptor signaling axis induce ovarian cancer stem cell regulation: studies based on the CRISPR/Cas9 system

[Corrigendum] Anthelmintic Pyrvinium Pamoate Blocks Wnt/β-catenin and Induces Apoptosis in Multiple Myeloma Cells

Correction To: Emerging Role of Lipid Metabolism Alterations in Cancer Stem Cells

Correction: Xiang, S., Et Al. Schisandrin B Induces Apoptosis and Cell Cycle Arrest of Gallbladder Cancer Cells. Molecules 2014, 19, 13235–13250

Erratum: Author correction to "The FAPα-activated prodrug Z-GP-DAVLBH inhibits the growth and pulmonary metastasis of osteosarcoma cells by suppressing the AXL pathway" [Acta Pharm Sin B 12 (2022) 1288-1304].

Correction: Shi, H., et al. Arctigenin Attenuates Breast Cancer Progression through Decreasing GM-CSF/TSLP/STAT3/β-Catenin Signaling. Int. J. Mol. Sci. 2020, 21, 6357

Correction to: Hsa-miR-623 suppresses tumor progression in human lung adenocarcinoma

Correction to: Increased MiR-221 expression in hepatocellular carcinoma tissues and its role in enhancing cell growth and inhibiting apoptosis in vitro

Publisher Correction: Precise targeting of POLR2A as a therapeutic strategy for human triple negative breast cancer (Nature Nanotechnology, (2019), 14, 4, (388-397), 10.1038/s41565-019-0381-6)